Tenofovir-Related Fanconi Syndrome with Nephrogenic Diabetes Insipidus in a Patient with Acquired Immunodeficiency Syndrome: The Role of Lopinavir-Ritonavir-Didanosine | Zendy

Florence Rollot | Zendy; E.-M. Nazal | Zendy; Laurence ChauvelotMoachon | Zendy; Charikleia Kelaïdi | Zendy; Nathalie Daniel | Zendy; Magdi Saba | Zendy; S. Abad | Zendy; P. Blanche | Zendy

Open Access

Tenofovir-Related Fanconi Syndrome with Nephrogenic Diabetes Insipidus in a Patient with Acquired Immunodeficiency Syndrome: The Role of Lopinavir-Ritonavir-Didanosine

Author(s) -

Florence Rollot,

E.-M. Nazal,

Laurence ChauvelotMoachon,

Charikleia Kelaïdi,

Nathalie Daniel,

Magdi Saba,

S. Abad,

P. Blanche

Publication year - 2003

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/379829

Subject(s) - didanosine , nephrogenic diabetes insipidus , lopinavir , medicine , ritonavir , fanconi syndrome , tenofovir , lopinavir/ritonavir , virology , protease inhibitor (pharmacology) , gastroenterology , pharmacology , diabetes insipidus , kidney , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy

Tenofovir-related tubular damage, like all other recently reported cases, occurred in patients receiving the protease inhibitor (PI) ritonavir, often with lopinavir. Increased plasma concentrations of didanosine were also observed after the addition of tenofovir. It was suspected that tenofovir with PIs interacted with renal organic anion transporters, leading to nephrotoxic tubular concentrations of tenofovir and systemic accumulation of didanosine. Until there is a better understanding of these interactions, close monitoring is recommended for patients receiving tenofovir, PIs, and didanosine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research